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The multikinase inhibitor sorafenib is, at present, the only drug approved for the treatment
of hepatocellular carcinoma (HCC), one of the most lethal types of cancer worldwide.
However, the increase in the number of sorafenib tumor resistant cells reduces efficiency.
A better knowledge of the intracellular mechanism of the drug leading to reduced cell
survival could help to improve the benefits of sorafenib therapy. Autophagy is a bulk
cellular degradation process activated in a broad range of stress situations, which allows
cells to degrade misfolded proteins or dysfunctional organelles. This cellular route can
induce survival or death, depending on cell status and media signals. Sorafenib, alone
or in combination with other drugs is able to induce autophagy, but cell response to the
drug depends on the complex integrative crosstalk of different intracellular signals. In
cancerous cells, autophagy can be regulated by different cellular pathways (Akt-related
mammalian target of rapamycin (mTOR) inhibition, 5′ AMP-activated protein kinase
(AMPK) induction, dissociation of B-cell lymphoma 2 (Bcl-2) family proteins from Beclin-
1), or effects of some miRNAs. Inhibition of mTOR signaling by sorafenib and diminished
interaction between Beclin-1 and myeloid cell leukemia 1 (Mcl-1) have been related
to induction of autophagy in HCC. Furthermore, changes in some miRNAs, such as
miR-30α, are able to modulate autophagy and modify sensitivity in sorafenib-resistant
cells. However, although AMPK phosphorylation by sorafenib seems to play a role in the
antiproliferative action of the drug, it does not relate with modulation of autophagy. In
this review, we present an updated overview of the effects of sorafenib on autophagy
and its related activation pathways, analyzing in detail the involvement of autophagy on
sorafenib sensitivity and resistance.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and the second most
frequent cause of cancer-related death worldwide (Ferlay et al., 2015; Torre et al., 2015). The
staging and recommended treatment of patients with HCC is related to the liver function, size and
number of nodules, general status of the patient, vascular invasion, and the presence of extrahepatic
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metastasis. Curative treatments such as surgical resection, liver
transplantation, and radiofrequency ablation may be useful
in the early stages of the disease. However, only palliative
treatments are available in advanced stages, in which different
chemotherapeutics have been assayed with variable effectiveness
(Rossi et al., 2010; Forner et al., 2012). The development of
new diagnostic methods which can detect small liver tumors is
essential to allow more aggressive interventions and to improve
patient survival rates (Gonzalez, 2014).
Sorafenib (BAY 43-9006, Nexavar R©), which was developed
in 1995 (Gauthier and Ho, 2013), is the only chemotherapeutic
drug which has demonstrated to improve survival rate in
patients with HCC (Llovet et al., 2008; Abdel-Rahman and
Fouad, 2014). Recent studies have also proven that sorafenib
has therapeutic effects in other cancer types, such as thyroid
cancer, acute myeloid leukemia, advanced renal cell carcinoma
or prostate cancer (Escudier et al., 2007; Gollob et al., 2007;
Chi et al., 2008; Antar et al., 2014; Luo et al., 2014; Alonso-
Gordoa et al., 2015; Yamamoto et al., 2015). Sorafenib targets
the RAF serine/threonine kinases, a family of three members
(A-RAF, B-RAF, and C-RAF/Raf-1) that play a key role in
the transduction of mitogenic and oncogenic signals through
the Raf/Mitogen-activated protein (MAP)/extracellular signal-
regulated kinase (ERK) kinase (MEK)/ERK signaling pathway,
resulting in a lower cyclin D1 expression and in cell cycle
arrest (Wellbrock et al., 2004; Adnane et al., 2006; Liu et al.,
2006). Sorafenib also potently inhibits tyrosine kinase receptors
such as vascular endothelial growth factor receptor (VEGFR) 2,
VEGFR 3, platelet-derived growth factor receptor-β (PDGFR-
β), Flt3, and c-Kit, which promote angiogenesis (Wilhelm
et al., 2004, 2008; Cervello et al., 2012). The repression
blocks a broad spectrum of different processes involved in
proliferation, angiogenesis or apoptosis, causing a reduction in
blood vessel area in the tumor and starving cancerous cells (Erber
et al., 2004; Gauthier and Ho, 2013). Furthermore, sorafenib
enhances TRAIL-induced cell death through SH2 domain-
containing tyrosine phosphatase (SHP-1)-dependent reduction
of signal transducers and activators of transcription type 3
(STAT3) phosphorylation (Tyr705STAT3) and related proteins
Mcl-1 (myeloid cell leukemia 1), survivin, and cyclin D1 in
hepatoma cells (Chen et al., 2010). Sorafenib is also able to repress
Mcl-1 activity through a MAPK-independent mechanism, which
increases the apoptosis intrinsic pathway in tumor cells (Yu et al.,
2005; Ulivi et al., 2009). Moreover, recent studies have claimed
that eIF4E (eukaryotic translation initiation factor 4E) might be
implicated in sorafenib-dependent Mcl-1 inhibition (Rahmani
et al., 2005).
Nowadays, sorafenib is the only Food and Drug
Administration (FDA)-approved HCC systemic therapy,
expanding patient mean survival from 7.9 to 10.7 months (Llovet
et al., 2008; Guan and He, 2011). Despite initial response, most
patients develop disease progression probably as a consequence
of tumor resistant cells which do not respond to this molecule,
mainly due to upregulation of some survival pathways which
may cover up the death signals induced by sorafenib. Therefore, a
better knowledge of those cellular routes is required to overcome
unwanted tumor resistance and consequently improve the
beneficial effects of sorafenib therapy (Knievel et al., 2014; Sakai
et al., 2015; Togashi and Nishio, 2015).
Macroautophagy (hereafter referred to as autophagy) is a
bulk degradation system which recycles unfolded, damaged,
or useless cellular components, like proteins or organelles, for
the maintenance of cellular homeostasis in order to promote
adaptation and cell survival (San-Miguel et al., 2014, 2015;
Vallejo et al., 2014). However, excessively stimulation may lead
to programmed cell death instead of survival (Tsujimoto and
Shimizu, 2005). In fact, its deregulation has been associated
with some diseases such as neurodegenerative disorders, diabetes,
cystic fibrosis, Crohn’s disease, diverse myopathies, hepatitis,
α-1 trypsin deficiency, cardiac hypertrophy, and tumorigenesis
(Mizushima and Komatsu, 2011). Autophagy is initiated with the
formation of a small membranous vesicle named phagophore
that elongates and engulfs a specific or unspecific portion of
the cytoplasm, forming a doubled-membranous structure named
autophagosome. Afterwards, this organelle fuses with a lysosome
and forms a combined vesicle or autophagolysosome, leading
to the degradation of the inner material by lysosomal enzymes,
releasing substances that become at disposal for the synthesis of
newly macromolecules formation or energy production (Tanida,
2011).
Autophagic process involves a highly conserved group
of macromolecules which were discovered in yeasts and
named as autophagy-related genes (Atg) (Tanida, 2011). In
mammals, five groups of proteins are involve in autophagosome
formation (Tanida, 2011). The first is ULK1 (unc-51-like kinase)
complex, whose functions are the recruitment of distinct Atg
components and the maintenance of phagophore integrity
(Mizushima, 2010). Next, Beclin1-Vps34 (vacuolar protein
sorting 34) complex allows membrane nucleation with formation
of PI3P (phosphatidylinositol 3-phosphate) (Yuan et al., 2013).
Afterwards, Atg9 and WIPI-1 (WD-repeat protein interacting
with phosphoinositides) system brings to phagophore some
lipids and proteins which are necessary for its elongation
(Orsi et al., 2010). Finally, two ubiquitin-like systems, Atg5-
Atg12-Atg16L and LC3 (microtubule-associated protein 1 light
chain 3), that conjugating with PE (phosphatidylethanolamine)
constitutes LC3-II (van der Veen and Ploegh, 2012), are both
required for autophagosome formation. The first system plays
an important role in the activation of the second one, and
LC3 protein is implicated in the elongation of autophagosome
membrane and in its closure (Sou et al., 2008).
There are various extracellular stimuli, such as nutrient
deprivation, growth factor withdrawal or hypoxia, which have
the ability to induce autophagy (He and Klionsky, 2009). Stress
situations, such as reactive oxygen species (ROS) accumulation
or endoplasmic reticulum (ER) stress can also modify this
cellular process (He and Klionsky, 2009). The most important
pathways involved in autophagy modulation are mTORC1
(mammalian target of rapamycin complex 1) and AMPK (5′
AMP-activated protein kinase). The first one abolishes autophagy
in presence of nutrients or growth factors, through ULK1
complex inhibition, while the second one promotes autophagy
when cellular energetic status is low (Sengupta et al., 2010;
Manwani and McCullough, 2013). On the other hand, some
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sphingolipids are also able to trigger autophagy (Li et al., 2014;
Ordoñez et al., 2015). Specifically, ceramide induces autophagy-
associated cell death, whereas sphingosine-1-phosphate induces
autophagy-associated survival (Li et al., 2014). The interaction
between Beclin-1 and Bcl-2 protein family, as well as the post-
transcriptional regulation by miRNAs have been related to
regulation of autophagy (Zhou et al., 2011; Sui et al., 2015).
Autophagy acts as a double-edged sword in cancer cells
because removes newlymutated cells and damagedmitochondria
in the early stage of the disease, but induces survival in
hypoxia and ischemia conditions, as well as promotes resistance
against some chemotherapeutic drugs and tumor progression
at the later phases (Eskelinen, 2011; Choi, 2012). In animal
models of hepatocarcinogenesis it has been described that
autophagy could play a protecting role during dysplastic phase
in normal hepatocytes, but promotes tumor cells growth during
the tumor-forming stage (Sun et al., 2013). Those apparently
controversial results can be related with the ability of autophagy
to reduce oxidative stress and maintain healthy mitochondria
preventing the initiation of hepatocarcinogenesis, while it blocks
the expression of p53 and other tumor suppressors during
late phases to promote the development of HCC (Tian et al.,
2015). Furthermore, some drugs used in cancer treatment induce
autophagy-related cell death in cancer cells (Scarlatti et al., 2004).
Thus, it is interesting to review the effects of this antitumor agent
on the autophagy process in HCC cells, and the influence of
autophagy on sorafenib-related cell resistance generation (Liu
et al., 2016). A better knowledge of the sorafenib autophagy-
related mechanisms could contribute to improve its therapeutic
efficiency, increasing cancer patient survival rates.
AUTOPHAGY INDUCTION BY SORAFENIB
Autophagy is usually deregulated in tumor cells whereas has
been related to cell survival and drug resistance. Sorafenib and
other chemotherapeutic drugs have been shown to modulate
autophagy in different in vitro and in vivo experimental models
(Gauthier and Ho, 2013). Sorafenib regulates autophagy in
various hepatocellular cell lines (Table 1). In particular, different
studies have shown the presence of acid vesicles which are typical
features of autophagosomes in sorafenib-treated cells (Table 1;
Park et al., 2008; Chiou et al., 2010; Shi et al., 2011; Shimizu
et al., 2012; Eum et al., 2013; Honma and Harada, 2013; Tai
et al., 2013; Fischer et al., 2014; Stiuso et al., 2015). Moreover,
sorafenib can also promote LC3 lipidation, an obvious sign of
autophagy induction (Tai et al., 2013; Yuan et al., 2014; Zhai
et al., 2014). For example, it has been observed that LC3-II
formation by sorafenib is dose-dependent and time-dependent
in HepG2, MHCC97-L, Huh7, HLF, and PLC/PRF/5 HCC cells
(Shi et al., 2011; Shimizu et al., 2012). In addition, sorafenib
modulates the expression of multiple autophagy markers. Thus,
the drug stimulates Beclin1, Atg5, and Atg12 expression in
HCC cells in vitro (Yuan et al., 2014), Beclin-1 expression is
increased by sorafenib in a time-dependent fashion in Hep3B
cells (Carr et al., 2013), sorafenib can mildly induce Beclin1
and Atg-5 expression whereas decreases p62 expression in a
significant manner in PLC-5 cells (Tai et al., 2013), or increases
Atg5, Vps34 and Beclin-1, decreases p62 and does not affect
UVRAG expression in Huh7 and HepG2 cells (Zhai et al., 2014).
Moreover, autophagy induced by sorafenib reaches the lysosome
degradatory phase, as demonstrated by using a mRFP-GFP-
LC3 combined fluorescent-tag (Shimizu et al., 2012). Several
discrepancies in autophagy induction have been also observed
in sorafenib-treated HCC cells (Chiou et al., 2010; Fischer
et al., 2014). This apparently paradoxical discrepancy and others,
about the effects of sorafenib in the autophagic mechanisms,
are included in the Table 2. Sorafenib also regulated autophagy
in non HCC cancer cells (Table 3) such as macrophages,
osteosarcoma, multiple myeloma, colorectal carcinoma cells,
prostate, mammary, thyroid, and renal cancer cells, (Walker
et al., 2009; Ullen et al., 2010; Bareford et al., 2011a,b; Pfisterer
et al., 2011; Kharaziha et al., 2012, 2013; Lin et al., 2013; Zheng
et al., 2015) through different pathways which are summarized in
the Table 3.
Some studies connect sorafenib administration and autophagy
modulation in experimental HCC models in vivo (Tables 1, 3).
In all research done until now, sorafenib can increase
autophagosome formation and modify autophagy markers
expression in a similar way to models in vitro (Shi et al., 2011;
Shimizu et al., 2012; Tai et al., 2013). The only study analyzing
the potential link between sorafenib and autophagy in patients
has been performed in refractory or relapsed lymphoproliferative
disease, demonstrating that LC3-II base levels are lower in non-
responsible patients compared to responders, and that patients
who respond to sorafenib show a higher reduction of LC3
expression after 1 month of treatment (Guidetti et al., 2012).
Regorafenib, a structural analog of sorafenib, induces
autophagosome formation in HCC cells similarly than sorafenib
(Carr et al., 2013; Tavallai et al., 2015). In another study, two
different sorafenib analogs, t-MTUCB and AUCMB, caused
autophagosome formation and LC3 lipidation in various HCC
cell lines (Wecksler et al., 2014). Finally, sc-59, a kinase-
independent derivate of sorafenib showed a higher autophagy
induction characterized by an increased ability to induce LC3-
lipidation and acid vesicles formation (Tai et al., 2013).
Some works have established that sorafenib induces
autophagy as a cellular survival mechanism in HCC because
when this pathway is repressed by a chemical drug (like
chloroquine or bafilomycin A1) or by a small interfering RNA
(siRNA) against Beclin-1 or Atg5, sorafenib kills more cancerous
cells and its antiproliferative ability improves, which means that
autophagy induced by that antitumor agent works as a protective
pathway (Park et al., 2010; Yuan et al., 2014). Moreover, similar
effects have been also described in other non HCC cancer cells
(Tables 1, 3; Martin et al., 2009; Walker et al., 2009; Kharaziha
et al., 2012; Zheng et al., 2015). However, other studies have
observed opposite results in HCC (Tables 1, 3; Eum et al.,
2013; Tai et al., 2013; Tavallai et al., 2015) and non-HCC cells
(Lian et al., 2012; Lin et al., 2012). Tumor cell resistance to
sorafenib can also be related to switch from autophagy-related
death to autophagy-related HCC cell survival (Zhai et al., 2014).
Moreover, another different way to generate sorafenib resistance
consists in the abolishment of autophagy induction. In fact,
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TABLE 1 | Effect of sorafenib on autophagy markers in HCC in vitro or in vivo models.
References Model Effects on autophagy
markers
Global effects Role of autophagy




Increase apoptosis on tumor cells (it
increases caspase 3, 8, and 9 activity, Bax
expression, and decreases Bcl-2 protein
levels)
Not assessed
Eum et al., 2013 Multidrug-resistant Ras-NIH
3T3/Mdr cells
↑LC3-positive vesicles Sorafenib raises HCC cell death through
the activation of autophagy pathway and
the inhibition of mTOR activity
Cell death
Fischer et al., 2014 Hep3B, HuH7 ↑LC3 lipidation only in HuH7, but
with no effects in Hep3B cells
Those cell lines have different autophagy
responsiveness to sorafenib and that
might be linked to generation of sorafenib
resistant cells
Not assessed
Shi et al., 2011 MHCC97-L, PLC/PRF/5, HepG2 ↑Autophagosome formation
↑LC3 lipidation
↑Atg5
IRE-1α signaling pathway of ER stress is
necessary for autophagy induction by
sorafenib
Cell survival
Shi et al., 2011 Nude mice ortothopically
implanted with MHCC97-L
↑CHOP Autophagy inhibition decrease tumor
volume in sorafenib and sorafenib +
cloroquine treated mice
Cell survival




Inhibition of autophagy increases cell
sensitivity to sorafenib
Cell survival
Shimizu et al., 2012 Xenograft tumors of HuH7 cells
in nude mice
↑LC3 lipidation Autophagy inhibition decrease tumor
volume in Sorafenib treated mice
Cell survival





Sorafenib induces autophagy through the
disruption of Beclin-1-Mcl-1 complex
Cell death
Tai et al., 2013 Nude mice injected with PLC-5 Autophagy induction Sorafenib induces autophagy in vivo
through p-STAT inhibition and abolishes
cancer proliferation
Cell death
Zhai et al., 2014 Sorafenib-resistant and sensitive
HepG2 and HuH7 cells.
↑LC3-II. Atg5, Vps34, Beclin1
↓p62 in both, resistant and
sensitive cells although resistant
cells show lower levels of that
markers
Lack of sorafenib-induced autophagy in
HCC cells leads to generation of
sorafenib-resistant cells
Protection in parental
cells, but promotion of
cell death in resistant
cell lines
Zhai et al., 2014 Mice injected with HuH7
resistant cells
Results in accordance to in vitro
assay
Autophagy behavior switch is able to
modify cell sensitiveness to sorafenib.
Results in accordance
to in vitro assay
it has been demonstrated that sorafenib resistant cells show
lower levels of autophagy markers such as LC3, Atg5, Vps34, or
Beclin1 (Zhai et al., 2014). For all these reasons, normalization of
autophagy may be one of the key mechanisms to avoid cellular
resistance to that antineoplastic agent (Zhai et al., 2014; Liu et al.,
2016).
EFFECTS ON AUTOPHAGY OF SORAFENIB
COMBINATION WITH OTHER DRUGS
Some studies have analyzed changes in autophagy modulation
in HCC cells treated with different sorafenib-based drug
combinations (Table 4). The administration of an inhibitor
of histone deacetylases (HDAC), enzyme implicated in the
regulation of gene transcription related to promotion or
progression of cancer (Dokmanovic et al., 2007; Giannini et al.,
2012), has been shown to suppress tumor cell proliferation. The
most important member of that group is vorinostat, the first
HDACi to be approved for human clinical use (Giannini et al.,
2012). When vorinostat is combined with sorafenib in HCC
cultured cells, cell viability decreases more than in cells treated
with sorafenib or, vorinostat alone (Park et al., 2008, 2010).
Furthermore, drug combination can induce a higher Beclin-1,
Atg5, or Atg12 expression and LC3 lipidation than treatment
with only one chemotherapeutic agent (Park et al., 2008; Yuan
et al., 2014). When Atg5 or Beclin-1 were silenced with siRNA
in those studies, viability decreased more in cancer cells than
in control cells, being the drop higher in the drug combination
treated group (Park et al., 2008; Yuan et al., 2014). This result is
compatible with the prosurvival properties of autophagy during
the antiproliferative synergistic effect of those drugs (Table 4;
Park et al., 2008; Martin et al., 2009; Yuan et al., 2014).
The low efficacy of doxorubicin, as a single agent in HCC, has
led to evaluate its activity in combined treatment with sorafenib
(Manov et al., 2011). Doxorubicin belongs to anthracyclines
group, a type of antibiotic which were first isolated from soil
bacteria (Yang et al., 2014), that can generate simultaneously
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TABLE 2 | Discrepancies existent between different sorafenib either in vivo or in vitro studies.
Condition First situation Second situation
LC3 ↑Levels in Huh7 cells, inducing more drug response (Fischer et al.,
2014)
Moderate ↑ levels in Hep3B cells, inducing less drug response (Fischer
et al., 2014).
Autophagy ↑Levels, protecting cancerous cells from cell death both in vitro an
in vivo models (Shimizu et al., 2012)
↑Levels, promoting programmed cellular death in cancerous cells both
in vitro an in vivo models (Tai et al., 2013)
Autophagy ↓Levels in drug combination, reducing side effects of both drugs
(Manov et al., 2011)
↑ Levels in drug combination, leading to enhance drug synergism (Yuan
et al., 2014)
mTORC1 ↓Phosphorylation, leading to autophagy induction and cell death (Zhai
et al., 2014; Zhang et al., 2015)
No changes in phosphorylation associated with sorafenib cell resistance
(Ramakrishnan et al., 2012)
mTORC1 ↓Phosphorylation by some of the analogs of sorafenib associated with
autophagy (Tavallai et al., 2015)
No changes in phosphorylation by some of the analogs of sorafenib, not
being autophagy induction dependent on that pathway (Wecksler et al.,
2014)
Akt ↓Expression associated with increments in cellular death both in vivo
and in vitro experiments (Eulitt et al., 2010)
↑Levels both in vivo and in vitro models, leading to induction of survival
autophagy, survival pathways, and increasing sorafenib cell resistance (Zhai
et al., 2014)
AMPK ↑Phosphorylation due to the generation of a reduction of ATP cellular
levels (Tesori et al., 2015)
↑Phosphorylation due to the release of ROS from mitochondria (Pignochino
et al., 2015)
AMPK ↑Phosphorylation without autophagy associated (Tesori et al., 2015) No changes in AMPK activation and no autophagy associated (Sviripa et al.,
2013)
ER stress ↑IRE-1α expression, leading to autophagy induction (Shi et al., 2011) ↑PERK expression, but non-autophagy induction associated (Shi et al.,
2011)
Sphingolipids ↑Ceramide formation at in vitro models, leading to induction of
autophagy and programmed cell death (Park et al., 2010)
↓Slightly S1P levels at in vivo models (Beljanski et al., 2011)
TABLE 3 | Effect of sorafenib on autophagy markers in other in vitro or in vivo cancerous models distinct of HCC.
References Model Effects on autophagy
markers
Global effects Role of
autophagy
Lin et al., 2013 Human macrophages ↑Autophagic vacuoles
↑LC3 lipidation
Sorafenib stimulates autophagy but it inhibits
phagocytosis and secretion of IL-10
Not assessed
Kharaziha et al., 2012 Myeloma cell lines LP1, RPMI-8226 ↑LC3 lipidation
↓p62
↑LC3-positive vesicles




Kharaziha et al., 2012 Myeloma patient samples ↑LC3 lipidation It induces cell death and autophagy Cell death
Kharaziha et al., 2012 Myeloma mice models ↑LC3 lipidation Sorafenib increases mice survival, reduces
tumor development and induces autophagy
pathway
Cell death
Walker et al., 2009 Sorafenib plus vorinostat treatment in
a colorectal cancer cell line, HCT116
↑LC3
lipidation ↑Atg5
Sorafenib treatment induces a slightly
amount of autophagy which is cytoprotective
and is stimulated by vorinostat cotreatment
Cell survival
Ullen et al., 2010 Prostate carcinoma cell lines DU145
and PC3
↑Autophagosome formation Sorafenib alters mitochondrial potential and
induces apoptosis and autophagy
Not assessed
Bareford et al., 2011b Fulvestrant-resistant and sensitive






Sorafenib induces autophagy pathway alone
or in combination with permetrexed, and that
induction sensitizes that cells to cell death
Cell death
Pfisterer et al., 2011 Human osteosarcoma cell line U2OS ↑WIPI
↑Autophagosome formation
Sorafenib induces autophagy in normal and
starved cells and that is induced by calcium
ion release to cytoplasm
Not assessed
Lin et al., 2012 Medullary thyroid cancer cell lines
MTG-1 and TT
↑LC3-II ↑Atg5 Sorafenib induces both autophagy and
apoptosis in that in vitro model
Cell death
Zheng et al., 2015 Diverse renal carcinoma cell lines like




↑LC3-II and LC3-II/I ratio
Sorafenib induces a cytoprotective form of
autophagy in renal carcinoma cells
Cell survival
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Global effect of both
drugs treatment
Yuan et al., 2014 Hepatocellular
carcinoma











Manov et al., 2011 Hepatocellular
carcinoma
In vitro Doxorubicin ↑LC3-II ↓LC3-II Sorafenib acts as an
antagonist of doxorubicin
Tavallai et al., 2015 Hepatocellular
carcinoma







effects on autophagy and
stimulate autophagic cell
death
Lam et al., 2015 Hepatocellular
carcinoma














































LC3-I/II only in the
same cell line as
sorafenib alone
Quercetin promotes
sorafenib cell death in both
cell lines but only induces
autophagy in one of them
















topoisomerase II poisoning, DNA adduct formation, ceramide
overproduction and oxidative stress (Yang et al., 2014). One
of the main problems of the use of doxorubicin alone in
therapy is the high number of side effects (Yang et al.,
2014). Interestingly, sorafenib decreases doxorubicin-related
autophagy, with a reduction of the expression of LC3 and its
lipidation (Table 4; Manov et al., 2011).
Sildenafil is another agent which has been combined with
sorafenib in HCC (Table 4; Tavallai et al., 2015). This drug
is able to inhibit phosphodiesterase 5, an enzyme which
transforms cyclic GMP (cGMP) into his inactive form (Das
et al., 2015). Sildenafil is used mainly in the treatment of
erectile dysfunction and of some cardiovascular diseases because
it produces vasodilatation (Das et al., 2015). It has also been
postulated that sildenafil is able to induce the intrinsic pathway of
apoptosis in colorectal carcinoma cells and lymphatic leukemia
cells (Booth et al., 2014; Das et al., 2015). Sildenafil increases
the antiproliferative properties of sorafenib and regorafenib
(Table 4; Tavallai et al., 2015). The combined treatment increases
autophagosome formation followed by the accumulation of
red fluorescence at 24 h into GFP-RFP-LC3- transfected HCC
cells. Moreover, the reduction of cell death by regorafenib and
sildenafil in cells treated with Atg5, Beclin-1, or ULK1 siRNA
suggests that autophagy may act as a pro-death mechanism in
this setting (Tavallai et al., 2015).
Sorafenib has also been combined with PHY906, an
herbal mixture which consists of four distinct components:
Glycyrrhiza uralensis, Paeonia lactiflora, Scutellaria baicalensis
roots, and Ziziphus jujuba fruit. This plant mixture is based
on an old Chinese formulation used for the treatment
of various gastrointestinal diseases, like diarrhea, fever, or
vomiting (Liu and Cheng, 2012; Rockwell et al., 2013).
Recent studies have shown the efficacy of PHY906 as a
chemotherapeutical adjuvant (Kummar et al., 2011). When
this herbal mixture is combined with sorafenib, expression of
autophagy markers increases. Paeonia lactiflora and Scutellaria
baicalensis are the critical components of that mixture in relation
to autophagy induction, because following suppression of those
plants from the herbal blend, LC3 is not lipidated (Table 4;
Lam et al., 2015).
Similarly, different combinations of sorafenib with other
drugs and antioxidants or herbal mixtures seem to be
able to modulate autophagy in non-liver cancer cells (see
Table 4).
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AUTOPHAGY-RELATED CELLULAR
PATHWAYS AND SORAFENIB TREATMENT
There are some proteins and cellular pathways in tumor cells
that can be involved in the regulation of autophagy by sorafenib.
Those regulatory routes have a changing effect, because they are
dependent on the cell state, its origin or some medium features.
The most important are described in detail in the following
sections (Figure 1).
mTOR Pathway
The mTOR pathway is one of the main regulators of cellular
metabolism in response to oxidative stress, unfolded protein
response, hypoxia, nutrients deprivation or growth factor
deficiency (Neufeld, 2010; Yang and Ming, 2012; Sarkar, 2013).
The inhibition of mTOR signaling by sorafenib is related
to induction of autophagy (Table 5, Figure 1). Most studies
have shown that sorafenib is able to decrease mTORC1
phosphorylation, expression, and activity both in cultured cells
in vitro and in xenograft tumor implantation in mice (Liu
et al., 2012; Zhai et al., 2014). In HCC in vitro models, it has
been described that sorafenib inhibits mTORC1 phosphorylation
during periods from 24 to 48 h (Zhai et al., 2014; Zhang et al.,
2015). Furthermore, sorafenib is able to dephosphorylate p70S6K
and 4E-BP1, which are two obvious evidences of mTORC1
activity inhibition in HCC cells (Liu et al., 2012) and other
cancers (Eulitt et al., 2010; Gulhati et al., 2012; Kharaziha et al.,
2012; Tang et al., 2012; Eum et al., 2013; Hamed et al., 2015).
However, it has been shown that sorafenib is not able to alter
phosphorylation status of mTORC1 but reduces p70S6K and
4EBP1 phosphorylation in cultured non-Hodgkin lymphoma cell
lines (Ramakrishnan et al., 2012). Other in vivo studies also
suggest that sorafenib is able to reduce mTORC1 activity in
HCC xenograft models followed by a decreased phosphorylation
of its downstream proteins, p70S6K, 4E-BP1, and eIF-4E (Liu
et al., 2012; Zhai et al., 2014). It has been shown that sorafenib
reduces in vivo and in vitro mTORC1 signaling and p70S6K
phosphorylation, but increases mTORC2 through increasing
Ser2481mTOR, being this later effect abolished by everolimus
co-treatment in osterosarcoma preclinical models (Figure 1;
Pignochino et al., 2013).
Some researchers have assessed if the induction of autophagy
by sorafenib is due to repression of mTOR signaling pathway in
HCC (Shimizu et al., 2012; Zhai et al., 2015) and other cancers
(Bareford et al., 2011a,b; Kharaziha et al., 2012; Eum et al., 2013).
Due to dual role of autophagy in cellular death, mTOR inhibition
might lead to death or survival of cancer cells, depending on
whether autophagy repressed by this protein works, respectively,
as a cell death inducer, or as a survival mechanism in both
HCC and non-HCC cells (Kharaziha et al., 2012; Shimizu et al.,
2012; Tavallai et al., 2015). Sorafenib analogs have a different
ability to abolish mTOR in cultured cell lines in vitro. Some
of them, such as regorafenib or SK-01105, are able to induce
mTOR dephosphorylation similarly to sorafenib, whereas other
compounds, like t-AUCMB or t-MTUCB, cannot inhibit mTOR
activity, so autophagy induction mediated by those sorafenib
analogs is not modulated by mTORC1 activity (Wecksler et al.,
2014; Tavallai et al., 2015).
The major upstream inducer of mTORC1 pathways is
PI3K/Akt signaling (Sarkar, 2013). In sorafenib-resistant cells,
Akt expression is usually over-stimulated, and treatment
with some specific repressors is able to increase sorafenib-
related cell death, which means that combined treatment with
sorafenib and an Akt inhibitor may be useful because it
might improve sorafenib sensitivity (Zhai et al., 2015). Different
reports have shown that sorafenib inhibits Akt activity and
its phosphorylation in HCC and renal carcinoma cells (RCC)
(Table 5; Eulitt et al., 2010; Gulhati et al., 2012; Serova et al., 2013;
Hamed et al., 2015; Zhang et al., 2015). However, other studies
found that sorafenib induces Akt phosphorylation, which will
TABLE 5 | Effect of sorafenib on mTOR/Akt pathway in tumor cells.
References Cell lines Pathophysiological condition Effect on markers of mTOR/Akt
pathway
Global effect
Hamed et al., 2015 GBM12 Glioblastoma multiforme ↓p-Akt
↓p-mTOR ↓p-p70
Sorafenib induces Akt/mTOR
pathway inhibition when have passed
only 6 h of treatment
Liu et al., 2012 PLC/PRF/5, HepG2
and Hep3B
Hepatocellular carcinoma ↓p-mTOR ↓p-p70S6K ↓p-4E-BP1
↑p-Akt
Two hours of treatment with sorafenib
is able to downregulate mTOR and all
its related pathways
Ramakrishnan et al., 2012 Dohh2 Non-Hodgkin lymphoma ↓p-p70 ↓p-4E-BP1 = p-mTOR Sorafenib fails in inactivate mTOR
phosphorylation at 8 h of treatment
Tang et al., 2012 GBM15 Glioblastoma multiforme ↓p-p70 = p-mTOR Twenty-Four hours of treatment with
sorafenib reduces slightly mTOR
pathway induction
Zhai et al., 2014 Huh7 and HepG2 Hepatocellular carcinoma ↓p-mTOR ↓p-p70S6K ↓p-4E-BP1
↑p-Akt
Sorafenib inhibits mTOR pathway
activity and that inactivation
stimulates autophagy response
Zhang et al., 2015 SMMC-772l Hepatocellular carcinoma ↓ Akt, PI3K and mTOR at 8 h of
treatment, afterwards their levels
increases
Sorafenib induces a transitory
inactivation of Akt/mTOR pathway
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FIGURE 1 | Sorafenib induces autophagy response through modulation of the main downstream factors and pathways. In this scheme, some of the
mediators of autophagy induction by sorafenib in tumor cells are represented. Sorafenib may induce AMPK pathway because it reduces ATP levels and increases
ROS, which leads to inhibition of mTORC1 signaling pathway. Sorafenib can also stimulate ER stress, specifically IRE-1α branch and all its downstream genes, and
release calcium ion to cytosol, which induces autophagosome formation. It may also disrupt Beclin-1 and Bcl-2 complex, with Beclin-1 release. Other non-protein
mediators which may be involved in sorafenib effects are miRNA30α and sphingolipids, because the drug can reduce miRNA30α signaling, which is a Beclin-1
repressor, induce ceramide formation, and reduce S1P levels, leading to autophagosome formation.
lead to generate resistance against that chemotherapeutic agent
(Table 5; Liu et al., 2012; Zhai et al., 2015). Finally, a third group
of works have reported that sorafenib has not influence in the
phosphorylation status of Akt (Gedaly et al., 2010).
In summary, sorafenib appears to inactivatemTORC1 activity,
which would contribute to autophagy induction. The mechanism
responsible for those effects remains unclear, but, in some cases,
could involve the PI3K/Akt pathway.
AMPK Pathway
AMPK is a heterotrimeric complex acting as a sensor of energy
status in eukaryotic cells (Grahame Hardie, 2014; Novikova
et al., 2015). AMPK activators may be used as adjuvants in
various cancer therapies, because its stimulation can induce
autophagy or cell cycle stop in tumor cell (Motoshima et al.,
2006; Donadon et al., 2010; Rehman et al., 2014). Sorafenib
activates AMPK being this effect potentially relevant during
induction of autophagy in cancer cells (Figure 1; Eum et al.,
2013; Fischer et al., 2014; Tesori et al., 2015). Sorafenib is able
to induce AMPK phosphorylation in a time-dependent fashion
and in a dose-dependent manner in experimental models in
vitro, specifically in cultured cells coming from different types
of human tumors (Eum et al., 2013; Fumarola et al., 2013;
Pignochino et al., 2013, 2015; Fischer et al., 2014; Groenendijk
et al., 2015; Tesori et al., 2015). It has been demonstrated that the
incubation with 5 µM of sorafenib in multidrug resistant cells
cultured in vitro can stimulate AMPK phosphorylation in a time-
dependent manner, starting at 0.5 h after treatment (Eum et al.,
2013). Sorafenib also induces AMPK phosphorylation (48 h) in
lung adenocarcinoma or non-small cell lung cancer (Groenendijk
et al., 2015). The drug is also able to induce AMPK activation
in various breast cancer cell lines (Fumarola et al., 2013). On
the other hand, there are some experimental models in which
sorafenib is not able to induce AMPK phosphorylation due to
the use of low concentrations of the antitumor agent (Sviripa
et al., 2013). Curiously, some differences in AMPK modulation
by sorafenib have been described between Huh7 and Hep3B
HCC cell lines, showing increases only in Huh7 cells but without
changes in Hep3B (Fischer et al., 2014).
There are two principal hypotheses which explain the
mechanism by which sorafenib induces AMPK phosphorylation
(Figure 1). The first one is that sorafenib generates a reduction
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in cellular ATP levels that increase AMP/ATP ratio and
AMPK activation (Fumarola et al., 2013; Tesori et al., 2015).
An experimental study which corroborates that hypothesis
demonstrated that ATP level in sorafenib-treated lung
adenocarcinoma cells decreases more than 50% compared
to the control group (Tesori et al., 2015). On the other hand, the
confirmation of the role of ROS burst during sorafenib-induced
AMP activation comes from a study in which AMPK-related
apoptosis was prevented by the treatment with a ROS scavenger
(Pignochino et al., 2013, 2015). The activation of upstream
kinases, LKB1 and CAMKKβ, is involved on sorafenib-
related AMPK activation in NSCLC cells in vitro and in vivo
(Groenendijk et al., 2015). Nevertheless, it seems that the AMPK
pathway could be not involved in autophagy-induction by
sorafenib, because LC3II expression increases sharply when
AMPK is inhibited in HCC cultured cells treated with sorafenib.
Whereby, it is possible that AMPK modulation by sorafenib
participates in other cellular processes, different to autophagy,
which can also take part into its antiproliferative action, such as
apoptosis or glucose metabolism deregulation (Pignochino et al.,
2013; Tesori et al., 2015).
Endoplasmic Reticulum Stress
Endoplasmic reticulum is the main cellular organelle where
protein synthesis, modification, and folding are carried out
and where calcium is stored. In the presence of different
stresses caused by physiological or pathological changes, non-
folding or unfolding proteins accumulate into the organelle,
generating a new condition inside the cell called ER stress.
ER stress is negatively interfering with protein synthesis and
affects other functions of that organelle, such as calcium
homeostasis, which finally may cause programmed cell death
(Tuñón et al., 2013; Kania et al., 2015). This situation leads
to the activation of the unfolded protein response (UPR),
which tries to recover the initial situation (Jheng et al., 2014).
Some of the strategies that this response uses to alleviate ER
stress are reduction of protein translation, expression of diverse
chaperones, induction of protein degradation processes, such
as ubiquitin-proteasome system, and degradation of portions
of the endoplasmic reticulum through the autophagy pathway
(Verfaillie et al., 2010). The three essential proteins in UPR
induction are inositol requiring enzyme 1α (IRE1α), protein
kinase R-like ER kinase (PERK) and activating transcription
factor (ATF6) (Crespo et al., 2012). These macromolecules are
located in basal conditions into the ER membrane and they
are inhibited by the chaperone binding immunoglobulin protein
(BiP). In stress situations, BiP disassembles of these molecules,
causing their activation and the stimulation of three different
protein cascades which promote the UPR (Malhi and Kaufman,
2011).
Sorafenib triggers the UPR response in different experimental
in vitro models, which may contribute to the sorafenib-related
induction of autophagy and to its antiproliferative effects
(Table 6, Figure 1). Sorafenib-induced UPR is unrelated to
MAPK inhibition because ERK repression cannot stimulate ER
stress (Rahmani et al., 2007; Shi et al., 2011). More in detail,
sorafenib is able to activate two of the three branches implicated
in the response against ER stress (Rahmani et al., 2007; Yi et al.,
2012). Specifically, this drug induces the expression of IRE1α
and PERK, whereas ATF6 expression remains constant without
changes in the expression on downstream proteins such as BiP
(Table 6; Rahmani et al., 2007; Yi et al., 2012). In fact, it has
been postulated that the effectiveness of ATF6 is consequence
of the profound alteration of the secretory pathway induced by
sorafenib (Yi et al., 2012). Other experiments have claimed that
sorafenib reduces directly BiP expression, chaperone related with
the induction of UPR mediated by this chemotherapeutic agent
(Table 6; Rahmani et al., 2007; Jiang et al., 2014).
Different research has demonstrated that sorafenib induces a
pronounced increase in the expression of PERK (Table 6), which
modifies the activity of all its downstream proteins (Rahmani
et al., 2007; Park et al., 2008; Shi et al., 2011; Yi et al., 2012; Holz
et al., 2013). One of the most important is eIF2α (eukaryotic
translation initiation factor 2α), is a tripartite protein complex
that binds and hydrolyzes GTP during its role in recruiting
the initiator methionyl-tRNA to the 40S ribosome to begin
mRNA translation in eukaryotic cells (Verfaillie et al., 2010).
Some studies have shown that sorafenib is able to induce eIF2α
phosphorylation on Ser51 when it has passed 2 h since the start
of the treatment (Rahmani et al., 2007; Yi et al., 2012; Dixon
et al., 2014). The phosphorylation of eIF2α prevents binding of
GTP and consequently reduces protein translation in cancer cells
(Rahmani et al., 2007; Yi et al., 2012).
The last of the UPR branches which is modified by sorafenib
is the IRE1α pathway. Some studies have suggested that
this antitumoral agent is able to stimulate IRE1α expression,
inducing its activation and changing the expression of different
downstream factors (Table 6, Figure 1; Rahmani et al., 2007; Shi
et al., 2011; Yi et al., 2012). In this way, IRE1α has a key role
in the splicing and subsequently translation of xbp1 (Malhi and
Kaufman, 2011), and sorafenib stimulates the splicing of this gene
similarly to the incubation with diverse ER stress inductors, such
as tunicamycin or thapsigargin (Yi et al., 2012). Curiously, when
IRE1α or xbp1 are knocked down, cell sensibility to sorafenib
increases (Rahmani et al., 2007).
The endoplasmic reticulum is the main reservoir of calcium
ion (Ca2+) (Kania et al., 2015). Sorafenib is able to disrupt
reticulum homeostasis because it discharges all the Ca2+
ion present in that organelle and induces its accumulation
into the cytosol (Rahmani et al., 2007). This reduction of
Ca2+endoplasmic reticulum storages increases ROS production,
inducing oxidative stress, and may contribute to the cancerous
cell death induced by sorafenib (Figure 1; Rahmani et al., 2007).
If ER stress is prolonged over time, UPR might be
overwhelmed because that organelle may be full of unfolded
and useless proteins, and that situation would generate
programmed cell death through CHOP (C/EBP homologous
protein) mediator, which is a transcription factor involved in
the increase of the expression of a lot of genes related with
apoptosis pathway (Verfaillie et al., 2010; Malhi and Kaufman,
2011). Sorafenib is able to induce the expression of CHOP and
of some proteases related with ER stress programmed cell death,
such as caspase-2 or -4 (Table 6). IRE1α has also been shown
to induce caspase-12 oligomerization through association with
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TABLE 6 | Effect of sorafenib on UPR proteins and related factors in cancerous cells.
References Cell lines Pathophysiological
condition
Model Effect on UPR-related
proteins
Global effect on ER stress
Dixon et al., 2014 HT-1080 Fibrosarcoma In vitro ↑eIF-2α
↑ATF4 = xbp1
Sorafenib leads to ER stress induction





Sorafenib promotes ER stress and the
UPR






Sorafenib induces upregulation of the ER
stress








Sorafenib alone and sorafenib combination
with vorinostat increases ER stress and
autophagy in a CD95 dependent manner









Sorafenib stimulates the UPR
independently of MAPK pathway inhibition








Sorafenib induces the UPR and that
generates autophagy and apoptosis
stimulation on these cells







↑gadd34 = ATF6a = BiP
Sorafenib activates only two of the three
branches of the UPR and that increases
autophagy flux
TRAF2/ASK (Yoneda et al., 2001). These results reflect that UPR
stimulation by that drug might be responsible, at least in a part,
for sorafenib-related programmed cell death in cultured cancer
cells (Rahmani et al., 2007; Niessner et al., 2011; Shi et al., 2011;
Yi et al., 2012; Holz et al., 2013).
Autophagy is one of the multiple pathways induced in
response to UPR upregulation, and that response might be one
of the cellular mechanisms through which sorafenib induces
autophagy (Fernández et al., 2015). It has been demonstrated
that the repression of the IRE1α pathway leads to complete
abolishment of autophagy induced by sorafenib (Figure 1; Shi
et al., 2011). On the other hand, PERK pathway inhibition barely
modifies the induction of autophagy by sorafenib (Shi et al.,
2011). Furthermore, prolonged activation of autophagy by the
drug, engulfing large ER portions with unfolded proteins and
alleviating ER stress, has been related with UPR inactivation
(Honma and Harada, 2013). In fact, autophagy suppression in
HCC cells using pharmacological inhibitors enhances the UPR
(Shi et al., 2011).
Sphingolipids
Sphingolipids are a broad group of bioactive lipids participating
in the regulation of multiple cellular routes, such as apoptosis,
cell cycle, senescence, or cell differentiation (Morales et al., 2012)
The most important ones are ceramides, which are a group of
molecules involved in cellular death, cell cycle stop or senescence
induction, and sphingosine-1-phosphate (S1P), a mediator in
cell survival or cell proliferation (Hannun and Obeid, 2008).
Autophagy is modulated by sphingolipid signaling, because
ceramides promote lysosome and autophagosome fusion, while
S1P disrupts that event. On the other hand, ceramides also
promote Beclin-1 and Bcl-2 disruption and alter ER Ca2+
homeostasis, which generates an early induction of apoptosis
(Harvald et al., 2015; Ordoñez et al., 2015). Therefore, alterations
in sphingolipids balance and signaling by sorafenib might
contribute to autophagy-induction mediated by that agent
(Harvald et al., 2015).
The number of articles relating changes in sphingolipid
generation and sorafenib effects are very few, and some of
them connect the balance of those lipids with the induction
of autophagy pathway (Figure 1). Sorafenib, in combination
with vorinostat, is able to induce the synthesis of diverse
ceramides, such as C14 or C16, mainly through of the
breakdown of more complex sphingolipids by ASMase (acid
sphingomyelinase), because inhibition of that enzyme generate
an obviously repression in the formation of that lipids (Park
et al., 2008). Nevertheless, it has been shown that de novo
synthesis would be also relevant in ceramide generation by that
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drug combination (Park et al., 2010). The inhibition of both
pathways into HCC cultured cells treated with sorafenib in
combination with vorinostat abolishes ROS production and ER
stress generation, which induces CD95 repression, and inhibition
of autophagy and cell death (Park et al., 2008, 2010). In summary,
ceramide formation by those chemotherapeutic drugs seems to
be necessary in the induction of cell death, ER stress, ROS
burden, and autophagosome formation in cultured cancer cell
(Park et al., 2008, 2010). A study has also demonstrated that
treatment with sorafenib decreased slightly the levels of S1P in
HepG2 xenograft tumors that were grown in mice (Beljanski
et al., 2011). In summary, it seems that sorafenibmight have some
effects on the misbalance of sphingolipid metabolism, but more
studies are necessary to elucidate its specific role, and to identify
the potential link with sorafenib-related autophagy induction
(Figure 1).
Beclin-1 and Bcl-2 Protein Family
Interaction
Beclin-1 is one of the most representative proteins taking
part at the beginning of the autophagy pathway (Yuan et al.,
2013). Recent studies have demonstrated the presence of a BH3
domain inside Beclin-1, through which it can bind to diverse
antiapoptotic proteins belonging to the Bcl-2 family, like Bcl-2,
Bcl-xL, or Mcl-1 (Germain et al., 2011). That interaction is able
to repress Beclin-1 activity, which generates a markedly decrease
on autophagy induction, being that situation reversed when
Beclin-1 BH3 domain is phosphorylated, because the phosphate
group prevents optimal binding between these two proteins,
causing their split, Beclin-1 release and its following activation
(Germain et al., 2011; Mukhopadhyay et al., 2014). There are
various cellular stimuli, as starvation or oxidative stress, which
alter Beclin-1 BH3 domain and, therefore, the optimal binding
between that two factors (Lindqvist et al., 2014). Moreover, other
proteins inside the cell with this domain, like BNIP3 or Nix, can
displace Beclin-1 and Bcl-2 binding, which results in Beclin-1
release (Campello et al., 2014).
Studies on different HCC cell lines and HCC-bearing mice
have shown that sorafenib treatment diminishes the interactions
between Beclin-1 and Mcl-1 and disrupt the complex constituted
by these proteins, inducing the release of Beclin-1 and the
formation of new autophagosomes (Figure 1; Tai et al., 2013).
However, interactions between Beclin-1 and other homologs of
Mcl-1, such as Bcl-xL, do not undergo significant changes in
autophagy induction (Tai et al., 2013). New experiments are
necessary for the complete elucidation of the role of Beclin-1 in
autophagy-induction mediated by sorafenib.
miRNAs Regulation
Some small non-coding RNA species can also participate in
the regulation of that pathway, specifically those that belong to
micro RNA (miRNA) group. These are constituted of about 20
to 24 nucleotides and its main function consists in deregulate
the expression of different messenger RNAs (mRNAs) in a
post-transcriptional manner (Elbashir et al., 2001; Yin and
Wan, 2002). This process implies the recognition of a miRNA
complementary sequence into the 3′-UTR region of the mRNA,
which leads to the binding between these two molecules. miRNA
is then able to inhibit mRNA translation causing, in the most of
the occasions, the break of the second nucleotide chain, and the
decrease of the expression of the protein which is encoded in that
mRNA (Elbashir et al., 2001; Yin and Wan, 2002). The sequence
that these molecules recognize in the mRNA is not exactly the
complementary one, and may have some different nucleotides
that prevent its perfect binding (Romaine et al., 2015). This
situation implies that mRNA inhibition is very plastic because
one mRNA expression can be modified by various miRNAs and
vice versa, due to only one miRNA can affect and modify the
translation of multiple mRNAs (Romaine et al., 2015).
There are some miRNAs involved in the regulation of the
autophagy process, such as miR-224, miR-30α, miR-855-3p, miR-
375, or miR-101. Their deregulation might be responsible of
changes in autophagy induction when the cellular homeostasis
is broken, for example, when a chemotherapeutic agent is
added to cultured cancer cells (Sui et al., 2015). Some studies
employing the resistant-hepatocyte rat model (R-H), which
allows dissecting the different steps of hepatocarcinogenesis,
showed that autophagy induction in early stage promotes the
growth of preneoplastic rat liver nodules, but in late stages
autophagy inhibition and miR-224 overexpression is found in
neoplastic nodules when compared to normal liver (Kowalik
et al., 2016). Furthermore, miR-224 upregulation has been
associated to impaired autophagy in both HCC human samples
and orthotopically rat models, suggesting an oncogenic role
in cell migration and correlating with a poor overall survival
rate in HCC (Lan et al., 2014). miR-30α is a miRNA that
can repress Beclin-1 expression, which generates a reduction in
autophagy activity. It has been found that its deregulation in
RCC cells would interfere with the induction of autophagy flux
by sorafenib and also alter sorafenib-related programmed cell
death through apoptosis (Zheng et al., 2015). The knockdown
of miR-30α by introducing antagomiR-30α increased Beclin-1
expression, and inhibited sorafenib-induced cytotoxicity, while
following overexpression, cells become more sensitive to the
drug. Therefore, the regulation of miR-30α may be crucial in
the decrease of the resistance of cancerous cells to sorafenib
(Figure 1; Zheng et al., 2015). Sorafenib has also been shown
to induce the expression of miR-423-5p in HCC models in vivo
and in vitro, and this stimulation produces a clear reduction
in HCC cell proliferation and autophagy induction, suggesting
that miR-423-5p could be used as a positive predictive marker
of sorafenib response in HCC patients (Stiuso et al., 2015).
In summary, it seems that some miRNAs are able to induce
autophagy in response to sorafenib treatment, which indicates
that its regulation is crucial to avoid sorafenib-related resistance
in cancerous cells.
CONCLUSIONS
Sorafenib is one of the most promising drugs for palliative
treatment in HCC, but the appearance of resistant cells, and
the rise of diverse side effects alter the optimal efficiency of
sorafenib therapy. Therefore, a better knowledge of mechanisms
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contributing to sorafenib resistance or sensitivity is required
for its optimal use. This review summarizes effects of sorafenib
on the autophagic process in HCC cells, and the influence of
autophagy on sorafenib-related cell resistance generation. This
agent, alone or in combination with other drugs, antioxidants,
or natural compounds is able to induce autophagy, causing either
cellular death or survival, which mainly depends on the complex
integrative crosstalk of different intracellular signals. Sorafenib-
related autophagy will generate cell drug resistance if it induces
the survival of cancer cells making them insensitive to death
stimulus. On the other hand, there are diverse cellular pathways,
protein interactions or nucleic acid molecules able to alter the
range of autophagy induction in response to sorafenib treatment.
Hence, changes in their activation may be useful to increase
sensitivity to sorafenib. Some intracellular pathways such as
mTOR pathway, UPR response, sphingolipid generation, and the
critical interaction of Bcl-2 and Mcl-1 with Beclin-1, as well as
changes in the miRNA cellular pattern are essential in the final
regulatory outcome of autophagy. Meanwhile, AMPK induction
fails to induce sorafenib-related autophagy. Further research is
needed to elucidate the role of autophagy in tumor cell resistance
to sorafenib. These studies could lead to the increase of the drug
effectiveness, reducing the doses of sorafenib in the treatment of
cancer diseases, or to the development of new sorafenib analogs
with less side effects and improved antiproliferative effects.
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